טוען...

Co-administration of dexamethasone increases severity and accelerates onset day of neutropenia in bladder cancer patients on methotrexate, vinblastine, adriamycin and cisplatin chemotherapy: a retrospective cohort study

BACKGROUND: Bladder cancer patients receiving methotrexate, vinblastine, adriamycin and cisplatin (MVAC) chemotherapy are co-administered with dexamethasone as an anti-emetic. We examined whether or not dexamethasone affects the severity and onset day of MVAC-induced severe neutropenia. METHODS: Thi...

תיאור מלא

שמור ב:

מידע ביבליוגרפי
הוצא לאור ב:	J Pharm Health Care Sci
Main Authors:	Itai, Shingo, Suga, Yukio, Hara, Yusuke, Izumi, Kouji, Maeda, Yuji, Kitagawa, Yasuhide, Ishizaki, Junko, Shimada, Tsutomu, Mizokami, Atsushi, Sai, Yoshimichi
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	BioMed Central 2017
נושאים:	Research Article
גישה מקוונת:	https://ncbi.nlm.nih.gov/pmc/articles/PMC5225533/ https://ncbi.nlm.nih.gov/pubmed/28097015 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40780-016-0072-5
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

Co-administration of dexamethasone increases severity and accelerates onset day of neutropenia in bladder cancer patients on methotrexate, vinblastine, adriamycin and cisplatin chemotherapy: a retrospective cohort study

פריטים דומים